Walter and Eliza Hall Institute of Medical Research

Csl Limited

Amrad Corporation Limited

The Council of Queensland Institute of Medical Research

The Council of the Queensland Institute of Medical Research (qimr)

The Council of the Queensland Institute of Medical Research

Andrew Mark Lew

Leonard Charles Harrison

Ken Shortman

Jefferey Stephen Boyle

George Rudy

Irina Caminschi

Brent Steven McKenzie

Margo Honeyman

Jamie Louise Brady

Jeffrey Stephen Boyle

Li Wu

Mireille Hanna Lahoud

Anna Irene Proietto

Mark Dexter Wright

Brent Mckenzie

Jefferey Boyle

Brent Steven Mckenzie

The present invention relates to the identification of proteins located on the cell surface of dendritic cells or precursors thereof, particularly antigen presenting dendritic cells. In particular, the present invention relates to compounds such as antibodies that bind these proteins. These compounds can be used to detect and/or enrich a subset of dendritic cells or precursors thereof. These compounds can also be used to target antigens to dendritic cells or precursors thereof to modulate a humoral and/or T cell mediated immune response to an antigen, or used to target cytotoxic agents to dendritic cells or precursors thereof involved in diseased states.

Dendritic cell marker and uses thereof

The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes that home to MAdCAMmucosal lymphoid tissues.

Relay vaccine

The present invention provides a method of raising an immune response in an animal. The method comprises administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety wherein the targeting moiety binds to at least one receptor present in circulatory vessels in Gut Associated Lymphoid Tissue. It is preferred that the targeting moiety binds to Mucosal Addressin Cellular Adhesion Molecule-1.

Antigen targeting

The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with antibodies or T-cells in subjects having pre-clinical or clinical Insulin-Dependent Diabetes Mellitus (IDDM). These molecules are preferentially immunoreactive to T-cells in subjects having pre-clinical or clinical IDDM and are useful in the development of diagnostic, therapeutic and prophylactic agents for IDDM.

Immunoreactive and immunotherapeutic molecules

The present invention provides methods of enhancing the immune response to an immunogen and to compositions for use in these methods. In particular the present invention provides a DNA molecule for use in raising an immune response to an antigen. The DNA molecule includes a first sequence encoding a targeting molecule, a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerization or multimerization of the product encoded by the DNA molecule.

Enhancement of immune response using targeting molecules

Immune response targeting molecules

Immunoreactive peptides

Growing community of inventors

Essendon, Australia

Andrew Mark Lew